ASH 2023 | Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
Catherine Broome, MD, Georgetown University Hospital, Washington, D.C., discusses an analysis of data from the ADVANCE IV randomized, double-blind Phase III trial (NCT04188379), which evaluated the use of intravenous efgartigimod in adults with persistent or chronic immune thrombocytopenia (ITP). This analysis investigated the time taken for patients to achieve a platelet count response and found that efgartigimod administration resulted in a rapidly occurring and clinically meaningful benefit when compared to placebo. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Sanofi, Alexion, Argenx, Apellis, Dianthus Therapeutics.
